-
Je něco špatně v tomto záznamu ?
Risk Score based on microRNA expression signature is independent prognostic classifier of glioblastoma patients
J. Sana, L. Radova, R. Lakomy, L. Kren, P. Fadrus, M. Smrcka, A. Besse, J. Nekvindova, M. Hermanova, R. Jancalek, M. Svoboda, M. Hajduch, P. Slampa, R. Vyzula, O. Slaby,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
NT13514
MZ0
CEP - Centrální evidence projektů
NT13581
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
Zdroj
NLK
Free Medical Journals
od 1996 do Před 1 rokem
Open Access Digital Library
od 1996-01-01
Medline Complete (EBSCOhost)
od 1996-01-01 do Před 1 rokem
PubMed
25322872
DOI
10.1093/carcin/bgu212
Knihovny.cz E-zdroje
- MeSH
- algoritmy MeSH
- DNA modifikační methylasy genetika MeSH
- enzymy opravy DNA genetika MeSH
- glioblastom genetika mortalita patologie MeSH
- lidé MeSH
- metylace DNA MeSH
- mikro RNA genetika MeSH
- míra přežití MeSH
- mozek metabolismus MeSH
- nádorové biomarkery genetika MeSH
- nádorové supresorové proteiny genetika MeSH
- nádory mozku genetika mortalita patologie MeSH
- následné studie MeSH
- prognóza MeSH
- proliferace buněk * MeSH
- promotorové oblasti (genetika) genetika MeSH
- retrospektivní studie MeSH
- staging nádorů MeSH
- stanovení celkové genové exprese * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Glioblastoma multiforme (GBM) is the most malignant primary brain tumor. The prognosis of GBM patients varies considerably and the histopathological examination is not sufficient for individual risk estimation. MicroRNAs (miRNAs) are small, non-coding RNAs that function as post-transcriptional regulators of gene expression and were repeatedly proved to play important roles in pathogenesis of GBM. In our study, we performed global miRNA expression profiling of 58 glioblastoma tissue samples obtained during surgical resections and 10 non-tumor brain tissues. The subsequent analysis revealed 28 significantly deregulated miRNAs in GBM tissue, which were able to precisely classify all examined samples. Correlation with clinical data led to identification of six-miRNA signature significantly associated with progression free survival [hazard ratio (HR) 1.98, 95% confidence interval (CI) 1.33-2.94, P < 0.001] and overa+ll survival (HR 2.86, 95% CI 1.91-4.29, P < 0.001). O(6)-methylguanine-DNA methyltransferase methylation status was evaluated as reference method and Risk Score based on six-miRNA signature indicated significant superiority in prediction of clinical outcome in GBM patients. Multivariate Cox analysis indicated that the Risk Score based on six-miRNA signature is an independent prognostic classifier of GBM patients. We suggest that the Risk Score presents promising prognostic algorithm with potential for individualized treatment decisions in clinical management of GBM patients.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15014022
- 003
- CZ-PrNML
- 005
- 20191021153958.0
- 007
- ta
- 008
- 150420s2014 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1093/carcin/bgu212 $2 doi
- 035 __
- $a (PubMed)25322872
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Šána, Jiří $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno 65653, Czech Republic, Faculty of Medicine, Masaryk University, Brno 62500, Czech Republic, Central European Institute of Technology, Masaryk University, Brno 62500, Czech Republic. $7 xx0165776
- 245 10
- $a Risk Score based on microRNA expression signature is independent prognostic classifier of glioblastoma patients / $c J. Sana, L. Radova, R. Lakomy, L. Kren, P. Fadrus, M. Smrcka, A. Besse, J. Nekvindova, M. Hermanova, R. Jancalek, M. Svoboda, M. Hajduch, P. Slampa, R. Vyzula, O. Slaby,
- 520 9_
- $a Glioblastoma multiforme (GBM) is the most malignant primary brain tumor. The prognosis of GBM patients varies considerably and the histopathological examination is not sufficient for individual risk estimation. MicroRNAs (miRNAs) are small, non-coding RNAs that function as post-transcriptional regulators of gene expression and were repeatedly proved to play important roles in pathogenesis of GBM. In our study, we performed global miRNA expression profiling of 58 glioblastoma tissue samples obtained during surgical resections and 10 non-tumor brain tissues. The subsequent analysis revealed 28 significantly deregulated miRNAs in GBM tissue, which were able to precisely classify all examined samples. Correlation with clinical data led to identification of six-miRNA signature significantly associated with progression free survival [hazard ratio (HR) 1.98, 95% confidence interval (CI) 1.33-2.94, P < 0.001] and overa+ll survival (HR 2.86, 95% CI 1.91-4.29, P < 0.001). O(6)-methylguanine-DNA methyltransferase methylation status was evaluated as reference method and Risk Score based on six-miRNA signature indicated significant superiority in prediction of clinical outcome in GBM patients. Multivariate Cox analysis indicated that the Risk Score based on six-miRNA signature is an independent prognostic classifier of GBM patients. We suggest that the Risk Score presents promising prognostic algorithm with potential for individualized treatment decisions in clinical management of GBM patients.
- 650 _2
- $a algoritmy $7 D000465
- 650 _2
- $a mozek $x metabolismus $7 D001921
- 650 _2
- $a nádory mozku $x genetika $x mortalita $x patologie $7 D001932
- 650 12
- $a proliferace buněk $7 D049109
- 650 _2
- $a metylace DNA $7 D019175
- 650 _2
- $a DNA modifikační methylasy $x genetika $7 D015254
- 650 _2
- $a enzymy opravy DNA $x genetika $7 D045643
- 650 _2
- $a následné studie $7 D005500
- 650 12
- $a stanovení celkové genové exprese $7 D020869
- 650 _2
- $a glioblastom $x genetika $x mortalita $x patologie $7 D005909
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mikro RNA $x genetika $7 D035683
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a promotorové oblasti (genetika) $x genetika $7 D011401
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a míra přežití $7 D015996
- 650 _2
- $a nádorové biomarkery $x genetika $7 D014408
- 650 _2
- $a nádorové supresorové proteiny $x genetika $7 D025521
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Radova, Lenka $u Central European Institute of Technology, Masaryk University, Brno 62500, Czech Republic.
- 700 1_
- $a Lakomý, Radek $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno 65653, Czech Republic, Faculty of Medicine, Masaryk University, Brno 62500, Czech Republic. $7 xx0164218
- 700 1_
- $a Křen, Leoš, $u Faculty of Medicine, Masaryk University, Brno 62500, Czech Republic, Department of Pathology, University Hospital Brno, Brno 62500, Czech Republic. $d 1966- $7 xx0081918
- 700 1_
- $a Fadrus, Pavel $u Faculty of Medicine, Masaryk University, Brno 62500, Czech Republic, Department of Neurosurgery, University Hospital Brno, Brno 62500, Czech Republic. $7 xx0123566
- 700 1_
- $a Smrčka, Martin, $u Faculty of Medicine, Masaryk University, Brno 62500, Czech Republic, Department of Neurosurgery, University Hospital Brno, Brno 62500, Czech Republic. $d 1965- $7 xx0000301
- 700 1_
- $a Besse, Andrej $u Central European Institute of Technology, Masaryk University, Brno 62500, Czech Republic.
- 700 1_
- $a Nekvindová, Jana $u Institute of Clinical Biochemistry and Diagnostics, Faculty of Medicine and Faculty Hospital in Hradec Kralove, Charles University, Hradec Kralove 50005, Czech Republic. $7 xx0207729
- 700 1_
- $a Hermanová, Markéta, $u Faculty of Medicine, Masaryk University, Brno 62500, Czech Republic, First Department of Pathological Anatomy, St. Anne's University Hospital, Brno 65691, Czech Republic. $d 1969- $7 xx0073982
- 700 1_
- $a Jančálek, Radim, $u Faculty of Medicine, Masaryk University, Brno 62500, Czech Republic, Department of Neurosurgery, St. Anne's University Hospital, Brno 65691, Czech Republic. $d 1975- $7 xx0037113
- 700 1_
- $a Svoboda, Marek, $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno 65653, Czech Republic, Faculty of Medicine, Masaryk University, Brno 62500, Czech Republic. $d 1975- $7 xx0098478
- 700 1_
- $a Hajdúch, Marián, $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc 77900, Czech Republic and. $d 1969- $7 xx0050218
- 700 1_
- $a Šlampa, Pavel, $u Faculty of Medicine, Masaryk University, Brno 62500, Czech Republic, Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Brno 65653, Czech Republic. $d 1960- $7 mzk2004257405
- 700 1_
- $a Vyzula, Rostislav, $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno 65653, Czech Republic, Faculty of Medicine, Masaryk University, Brno 62500, Czech Republic. $d 1952- $7 nlk20000083661
- 700 1_
- $a Slabý, Ondřej, $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno 65653, Czech Republic, Faculty of Medicine, Masaryk University, Brno 62500, Czech Republic, Central European Institute of Technology, Masaryk University, Brno 62500, Czech Republic, on.slaby@gmail.com. $d 1981- $7 js20030220015
- 773 0_
- $w MED00001050 $t Carcinogenesis $x 1460-2180 $g Roč. 35, č. 12 (2014), s. 2756-2762
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25322872 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20150420 $b ABA008
- 991 __
- $a 20191021154431 $b ABA008
- 999 __
- $a ok $b bmc $g 1071603 $s 896900
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 35 $c 12 $d 2756-2762 $i 1460-2180 $m Carcinogenesis $n Carcinogenesis $x MED00001050
- GRA __
- $a NT13514 $p MZ0
- GRA __
- $a NT13581 $p MZ0
- LZP __
- $a Pubmed-20150420
